SAB Biotherapeutics, Inc. — All Filings
402 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
25-NSE
3
4
4/A
424B3
424B4
424B5
425
5
8-A12B
8-K
8-K/A
AW
CERT
CORRESP
D
DEF 14A
DEFA14A
DRSLTR
EFFECT
NT 10-K
NT 10-Q
POS AM
PRE 14A
RW
S-1
S-1/A
S-3
S-3/A
S-4
S-4/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | 4 | 0000950170-24-019460 | Feb 23, 2024 | Feb 21, 2024 |
| 4 | 4 | 0000950170-24-019434 | Feb 23, 2024 | Feb 21, 2024 |
| 4 | 4 | 0000950170-24-019441 | Feb 23, 2024 | Feb 21, 2024 |
| S-8 | S-8 | 0000950170-24-019383 | Feb 23, 2024 | — |
| 4 | 4 | 0000950170-24-019430 | Feb 23, 2024 | Feb 21, 2024 |
| 4 | 4 | 0000950170-24-019432 | Feb 23, 2024 | Feb 21, 2024 |
| SC 13G/A | SC 13G/A | 0001104659-24-022778 | Feb 14, 2024 | — |
| SC 13G | SAB BIOTHERAPEUTICS, INC. | 0000902664-24-001535 | Feb 14, 2024 | — |
| SC 13G/A | — | 0001493152-24-006626 | Feb 14, 2024 | — |
| 8-K | 8-K | 0000950170-24-010093 | Feb 2, 2024 | Jan 30, 2024 |
| 8-K | 8-K | 0000950170-24-007941 | Jan 26, 2024 | — |
| 424B5 | 424B5 | 0000950170-24-007904 | Jan 26, 2024 | — |
| 8-K | 8-K | 0000950170-24-007480 | Jan 25, 2024 | Jan 23, 2024 |
| 8-K | 8-K | 0000950170-24-005793 | Jan 19, 2024 | — |
| 8-K | 8-K | 0000950170-24-000543 | Jan 3, 2024 | Jan 2, 2024 |
| DEF 14A | DEF 14A | 0000950170-23-070950 | Dec 18, 2023 | — |
| PRE 14A | PRE 14A | 0000950170-23-069098 | Dec 8, 2023 | — |
| 4 | 4 | 0000950170-23-068922 | Dec 8, 2023 | Dec 7, 2023 |
| SC 13G | SCHEDULE 13G | 0000921895-23-002708 | Dec 4, 2023 | — |
| 4 | 4 | 0000950170-23-067072 | Nov 30, 2023 | — |
| 4 | 4 | 0000950170-23-066901 | Nov 30, 2023 | Nov 29, 2023 |
| 8-K | 8-K | 0000950170-23-066553 | Nov 29, 2023 | — |
| 4 | 4 | 0000950170-23-066394 | Nov 28, 2023 | Nov 24, 2023 |
| 4 | 4 | 0000950170-23-066395 | Nov 28, 2023 | Nov 24, 2023 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-23-021502 | Nov 28, 2023 | Nov 24, 2023 |
| EFFECT | — | 9999999995-23-003472 | Nov 28, 2023 | — |
| CORRESP | — | 0000950170-23-066005 | Nov 24, 2023 | — |
| 8-K | 8-K | 0000950170-23-065895 | Nov 22, 2023 | — |
| 3 | 3 | 0000950170-23-065888 | Nov 22, 2023 | Nov 14, 2023 |
| S-3/A | S-3/A | 0000950170-23-065147 | Nov 20, 2023 | — |
| 8-K | 8-K | 0000950170-23-065178 | Nov 20, 2023 | Nov 14, 2023 |
| 4/A | AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-23-020902 | Nov 15, 2023 | Nov 10, 2023 |
| 4/A | 4/A | 0000950170-23-064323 | Nov 15, 2023 | Nov 10, 2023 |
| DEFA14A | DEFA14A | 0000950170-23-063776 | Nov 14, 2023 | — |
| 4 | 4 | 0000950170-23-063918 | Nov 14, 2023 | Nov 10, 2023 |
| 8-K/A | 8-K/A | 0000950170-23-063774 | Nov 14, 2023 | Sep 29, 2023 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-23-020791 | Nov 14, 2023 | Nov 10, 2023 |
| 10-Q | 10-Q | 0000950170-23-063076 | Nov 13, 2023 | Sep 30, 2023 |
| UPLOAD | — | 0000000000-23-012205 | Nov 7, 2023 | — |
| 4 | 4 | 0000950170-23-058894 | Nov 3, 2023 | Oct 30, 2023 |
| S-3 | S-3 | 0000950170-23-058898 | Nov 3, 2023 | — |
| 3 | 3 | 0000950170-23-058886 | Nov 3, 2023 | Oct 30, 2023 |
| DEF 14A | DEF 14A | 0000950170-23-056434 | Oct 30, 2023 | — |
| 8-K | 8-K | 0000950170-23-056048 | Oct 27, 2023 | Oct 23, 2023 |
| 4 | 4 | 0000950170-23-054936 | Oct 24, 2023 | Oct 23, 2023 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-23-019668 | Oct 24, 2023 | Oct 23, 2023 |
| PRE 14A | PRE 14A | 0000950170-23-054396 | Oct 20, 2023 | — |
| SC 13G | — | 0001493152-23-037345 | Oct 16, 2023 | — |
| D | — | 0001209191-23-052843 | Oct 16, 2023 | — |
| 3 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-23-019183 | Oct 10, 2023 | Oct 2, 2023 |